BioTuesdays

Tag - Roth Capital Partners

CymaBay

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

Stealth BioTherapeutics Logo

Roth starts Stealth BioTherapeutics at buy; PT $9

Roth Capital Partners launched coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and $9 price target. The stock closed at $1.59 on April 13. Stealth is focused on developing drugs targeted for rare...

soliton-logo

Roth starts Soliton at buy; PT $14

Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...

Immunic

Roth starts Immunic at buy; PT $44

Roth Capital Partners launched coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $44 price target. The stock closed at $5.74 on March 24. Immunic is focused on developing innovative new modulators of the immune...

X4 Pharma

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

Hepion Pharmaceuticals

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

Cellectar Biosciences

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...